Cargando…

Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study

BACKGROUND: Oral immunotherapy (OIT) has been recognized as a promising treatment for severe and long-lasting cow's milk (CM) allergy. Once maintenance has been achieved, patients should maintain daily intake of CM to ensure desensitization. Clinical experience concerning long-term follow-up is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mota, Inês, Piedade, Susana, Gaspar, Ângela, Benito-Garcia, Filipe, Sampaio, Graça, Borrego, Luís Miguel, Morais-Almeida, Mário
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073178/
https://www.ncbi.nlm.nih.gov/pubmed/30079306
http://dx.doi.org/10.5415/apallergy.2018.8.e28
_version_ 1783344134591873024
author Mota, Inês
Piedade, Susana
Gaspar, Ângela
Benito-Garcia, Filipe
Sampaio, Graça
Borrego, Luís Miguel
Morais-Almeida, Mário
author_facet Mota, Inês
Piedade, Susana
Gaspar, Ângela
Benito-Garcia, Filipe
Sampaio, Graça
Borrego, Luís Miguel
Morais-Almeida, Mário
author_sort Mota, Inês
collection PubMed
description BACKGROUND: Oral immunotherapy (OIT) has been recognized as a promising treatment for severe and long-lasting cow's milk (CM) allergy. Once maintenance has been achieved, patients should maintain daily intake of CM to ensure desensitization. Clinical experience concerning long-term follow-up is scarce. OBJECTIVE: The authors aimed to assess long-term efficacy and safety of a maintenance phase of OIT in real life. METHODS: Prospective study of all children and adolescents, who underwent CM-OIT and were subsequently followed at our allergy center on maintenance dose (200 mL daily) for at least 36 months after reaching the maintenance phase (from 2009 to 2016). RESULTS: Forty-two patients were enrolled: 60% male, 36% with history of anaphylaxis and 57% with asthma. The median time of follow-up was 69 months (range, 39–105 months) and the median age at the last clinical evaluation was 13 years (range, 6–23 years). Regarding adherence to the protocol: 92% are on free diet (at least 200 mL of CM daily; 7-g protein); 14% had transient interruptions and 7% definitely withdrawn with loss of tolerance. During maintenance, 45% developed mild to severe allergic reactions, and 7% had more than 3 episodes. A positive correlation between the occurrence of allergic reactions and history of anaphylaxis (p < 0.001) was found. The coexistence of asthma was risk factor for the occurrence of allergic reactions during maintenance. CONCLUSION: This real-life study supports long-term efficacy and safety of CM-OIT. Despite daily intake, 41% had symptoms at some moment during the complete follow-up period; a total of 33 symptomatic days in patients with mean follow-up time of 67.5 months. Clinical tolerance depends on daily intake. The protective effect reached can be lost after CM withdrawal. History of anaphylaxis was a risk factor for the occurrence of allergic reactions during the maintenance phase.
format Online
Article
Text
id pubmed-6073178
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Asia Pacific Association of Allergy, Asthma and Clinical Immunology
record_format MEDLINE/PubMed
spelling pubmed-60731782018-08-03 Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study Mota, Inês Piedade, Susana Gaspar, Ângela Benito-Garcia, Filipe Sampaio, Graça Borrego, Luís Miguel Morais-Almeida, Mário Asia Pac Allergy Original Article BACKGROUND: Oral immunotherapy (OIT) has been recognized as a promising treatment for severe and long-lasting cow's milk (CM) allergy. Once maintenance has been achieved, patients should maintain daily intake of CM to ensure desensitization. Clinical experience concerning long-term follow-up is scarce. OBJECTIVE: The authors aimed to assess long-term efficacy and safety of a maintenance phase of OIT in real life. METHODS: Prospective study of all children and adolescents, who underwent CM-OIT and were subsequently followed at our allergy center on maintenance dose (200 mL daily) for at least 36 months after reaching the maintenance phase (from 2009 to 2016). RESULTS: Forty-two patients were enrolled: 60% male, 36% with history of anaphylaxis and 57% with asthma. The median time of follow-up was 69 months (range, 39–105 months) and the median age at the last clinical evaluation was 13 years (range, 6–23 years). Regarding adherence to the protocol: 92% are on free diet (at least 200 mL of CM daily; 7-g protein); 14% had transient interruptions and 7% definitely withdrawn with loss of tolerance. During maintenance, 45% developed mild to severe allergic reactions, and 7% had more than 3 episodes. A positive correlation between the occurrence of allergic reactions and history of anaphylaxis (p < 0.001) was found. The coexistence of asthma was risk factor for the occurrence of allergic reactions during maintenance. CONCLUSION: This real-life study supports long-term efficacy and safety of CM-OIT. Despite daily intake, 41% had symptoms at some moment during the complete follow-up period; a total of 33 symptomatic days in patients with mean follow-up time of 67.5 months. Clinical tolerance depends on daily intake. The protective effect reached can be lost after CM withdrawal. History of anaphylaxis was a risk factor for the occurrence of allergic reactions during the maintenance phase. Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2018-07-23 /pmc/articles/PMC6073178/ /pubmed/30079306 http://dx.doi.org/10.5415/apallergy.2018.8.e28 Text en Copyright © 2018. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mota, Inês
Piedade, Susana
Gaspar, Ângela
Benito-Garcia, Filipe
Sampaio, Graça
Borrego, Luís Miguel
Morais-Almeida, Mário
Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
title Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
title_full Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
title_fullStr Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
title_full_unstemmed Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
title_short Cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
title_sort cow's milk oral immunotherapy in real life: 8-year long-term follow-up study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073178/
https://www.ncbi.nlm.nih.gov/pubmed/30079306
http://dx.doi.org/10.5415/apallergy.2018.8.e28
work_keys_str_mv AT motaines cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy
AT piedadesusana cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy
AT gasparangela cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy
AT benitogarciafilipe cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy
AT sampaiograca cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy
AT borregoluismiguel cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy
AT moraisalmeidamario cowsmilkoralimmunotherapyinreallife8yearlongtermfollowupstudy